

**UPDATE to the MEDSTAR FAMILY CHOICE FORMULARY
District of Columbia Healthy Families and Healthcare Alliance
March 2017 Pharmacy and Therapeutics Committee Meeting**

Quarterly updates will be available on this Website and more frequently on ePocrates.

CHANGES BELOW WILL BECOME EFFECTIVE ON OR AROUND APRIL 15, 2017

Additions:

- Differin Gel 0.1% OTC

Additions with Prior Authorization:*

- **Rubraca (rucaparib)**- indicated as monotherapy for the treatment of patients with deleterious breast cancer susceptibility gene (BRCA) mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies.

**Please see the PA Table on the MFC website for details of the requirements for approval and guidance on submission of clinical information*

Removals:

- None

Removal of Prior Authorization:

- None

Managed Drug Limitations & Step Therapy**

- None

*Details of the Prior Authorization Criteria are on this website in the Prior Authorization Table.

**Details of the Step Therapy Criteria are on this website in the Step Therapy Table.